Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool.

Delpu Y, Lulka H, Sicard F, Saint-Laurent N, Lopez F, Hanoun N, Buscail L, Cordelier P, Torrisani J.

PLoS One. 2013;8(1):e55513. doi: 10.1371/journal.pone.0055513. Epub 2013 Jan 31.

2.

The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis.

Hanoun N, Delpu Y, Suriawinata AA, Bournet B, Bureau C, Selves J, Tsongalis GJ, Dufresne M, Buscail L, Cordelier P, Torrisani J.

Clin Chem. 2010 Jul;56(7):1107-18. doi: 10.1373/clinchem.2010.144709. Epub 2010 Apr 29.

3.

Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.

Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W, Cui J, Du Y, Wei D, Huang S, Xie K.

Gastroenterology. 2014 Aug;147(2):485-97.e18. doi: 10.1053/j.gastro.2014.04.048. Epub 2014 May 20.

PMID:
24859161
4.

MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.

Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, Maghnouj A, Mirmohammadsadegh A, Hahn SA, Tannapfel A.

Lab Invest. 2011 Oct;91(10):1472-9. doi: 10.1038/labinvest.2011.99. Epub 2011 Jun 27.

5.

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.

Dhayat SA, Mardin WA, Seggewiß J, Ströse AJ, Matuszcak C, Hummel R, Senninger N, Mees ST, Haier J.

PLoS One. 2015 Nov 25;10(11):e0143755. doi: 10.1371/journal.pone.0143755. eCollection 2015.

6.

MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.

Yao J, Li Z, Wang X, Xu P, Zhao L, Qian J.

Acta Biochim Biophys Sin (Shanghai). 2016 Feb;48(2):202-8. doi: 10.1093/abbs/gmv129. Epub 2016 Jan 11.

PMID:
26758190
7.

MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.

Xue Y, Abou Tayoun AN, Abo KM, Pipas JM, Gordon SR, Gardner TB, Barth RJ Jr, Suriawinata AA, Tsongalis GJ.

Cancer Genet. 2013 Jun;206(6):217-21. doi: 10.1016/j.cancergen.2013.05.020. Epub 2013 Aug 9.

PMID:
23933230
8.

Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.

Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.

Cancer Lett. 2016 Aug 28;379(1):1-11. doi: 10.1016/j.canlet.2016.05.024. Epub 2016 May 24.

PMID:
27233476
9.

miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.

Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K, Miao Y.

Oncol Rep. 2013 May;29(5):1769-76. doi: 10.3892/or.2013.2297. Epub 2013 Feb 21.

PMID:
23440261
10.

Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.

Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y.

Gastroenterology. 2013 May;144(5):1086-1097.e9. doi: 10.1053/j.gastro.2013.01.058. Epub 2013 Feb 7.

PMID:
23395645
11.

MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3.

Li Z, Li X, Yu C, Wang M, Peng F, Xiao J, Tian R, Jiang J, Sun C.

Tumour Biol. 2014 Dec;35(12):11751-9. doi: 10.1007/s13277-014-2271-8. Epub 2014 Oct 26.

PMID:
25344675
12.

ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma.

Yonemori K, Seki N, Kurahara H, Osako Y, Idichi T, Arai T, Koshizuka K, Kita Y, Maemura K, Natsugoe S.

Cancer Sci. 2017 Jan;108(1):124-135. doi: 10.1111/cas.13119.

13.

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U.

Cancer Res. 2010 Jun 1;70(11):4528-38. doi: 10.1158/0008-5472.CAN-09-4467. Epub 2010 May 11.

14.

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.

Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, Bernhardt M, Ghadimi BM, Gaida MM, Bergmann F, Werner J, Ried T, Hanna N, Alexander HR, Hussain SP.

Cancer Res. 2016 Jul 1;76(13):3838-50. doi: 10.1158/0008-5472.CAN-15-2841. Epub 2016 Apr 20.

15.

MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.

Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR.

PLoS One. 2013 Aug 22;8(8):e71978. doi: 10.1371/journal.pone.0071978. eCollection 2013.

16.

MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.

Zhou L, Zhang WG, Wang DS, Tao KS, Song WJ, Dou KF.

Oncol Rep. 2014 Oct;32(4):1734-40. doi: 10.3892/or.2014.3374. Epub 2014 Aug 1.

PMID:
25109303
17.

Targeting miR-21 for the therapy of pancreatic cancer.

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P.

Mol Ther. 2013 May;21(5):986-94. doi: 10.1038/mt.2013.35. Epub 2013 Mar 12.

18.

miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1.

Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H, Wang W, Huang X, Yuan Z, Ai K.

J Exp Clin Cancer Res. 2014 Jun 25;33:54. doi: 10.1186/1756-9966-33-54.

19.

A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.

Kent OA, Mullendore M, Wentzel EA, López-Romero P, Tan AC, Alvarez H, West K, Ochs MF, Hidalgo M, Arking DE, Maitra A, Mendell JT.

Cancer Biol Ther. 2009 Nov;8(21):2013-24.

20.

Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.

Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J.

Ann Surg Oncol. 2009 Aug;16(8):2339-50. doi: 10.1245/s10434-009-0531-4. Epub 2009 May 28.

PMID:
19475450

Supplemental Content

Support Center